Results 121 to 130 of about 30,754 (261)

Definition, epidemiology, and burden of disease: HFpEF

, 2018
Heart failure with preserved ejection fraction (HFpEF) is a global pandemic, affecting half of the heart failure population and with an incidence and prevalence expected to increase further with an ageing population.
Lars H. Lund, Gianluigi Savarese
core   +1 more source

Baseline vs. on-treatment heart failure with preserved ejection fraction (HFpEF) in a real world cardio-oncology clinic: observational analysis of cancer therapy-related cardiovascular toxicity incidence and cancer treatment implications

Frontiers in Cardiovascular Medicine
Background and aimsHeart failure with preserved ejection fraction (HFpEF) prevalence increases, but in cancer patients undergoing potentially cardiotoxic treatments, HFpEF is not included in baseline risk stratification, nor in cancer therapy-related ...
Berlinde von Kemp, Xavier Galloo, Bram Roosens, Bart Neyns, Rik Schots, Mark De Ridder, Bernard Cosyns   +6 more
doaj   +1 more source

Can HFpEF and HFrEF Coexist? [PDF]

Circulation, 2020
Gabriele G. Schiattarella, Dan Tong, Joseph A. Hill   +2 more
openaire   +3 more sources

Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease

ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı, Ömer Faruk Akçay, Emre Yaşar, Ülver Derici, Galip Güz   +4 more
wiley   +1 more source

Metabolic remodelling in anthracycline cardiotoxicity: mechanisms and therapeutic insights

British Journal of Pharmacology, EarlyView.
Cardiac metabolic remodelling in anthracycline‐induced cardiomyopathy and metabolically oriented cardioprotective strategies. Schematic representation of substrate utilization, mitochondrial bioenergetic function and metabolic flexibility in the healthy heart, in anthracycline‐induced cardiomyopathy and under potential cardioprotective interventions ...
Giulia Guerra, Francesco Niro, Marco Mergiotti, Giovanni Gavatorta, Emilio Hirsch, Alessandra Ghigo   +5 more
wiley   +1 more source

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest, Priyanka Majety, Stéphanie B. Mayer, Om P. Ganda   +3 more
wiley   +1 more source

Body Composition Remodelling During GLP‐1‐Based Therapy: A Systematic Review and Meta‐Analysis Using a Hierarchical Physiological Framework

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Body composition changes during glucagon‐like peptide‐1 (GLP‐1)‐based therapy remain incompletely characterized, particularly regarding their effects on adiposity, muscle quantity, and muscle quality. We conducted a systematic review and meta‐analysis using a predefined physiological framework to evaluate body composition ...
Maria Luizza Lopes Menezes, Maria Eduarda Güntzel Chiappa, Rodrigo Fuentes Kloss, Marcelo Tuesta, Paula Santos, Alberto Souza Sá Filho, Gaspar R. Chiappa   +6 more
wiley   +1 more source

Effectiveness of Adding GLP‐1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individually, sodium–glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been shown to reduce major kidney and cardiovascular events in patients with chronic kidney disease (CKD). However, evidence supporting combined GLP‐1RA and SGLT2i therapy in this population remains limited.
Hussain Salim, Shaheer Qureshi, Gaurav S. Gulsin, Habib R. Khan, Saad Ahmed Waqas, Gerry P. McCann, Amit Garg, Mohammed Shurrab, Kamlesh Khunti, Muhammad Rashid   +9 more
wiley   +1 more source

Focus on HFpEF in heart failure

Chinese Medical Journal, 2022
Chunhui He, Rongchong Huang, Ningning Wang   +2 more
openaire   +3 more sources

Chd4 and ThPOK cooperate to preserve structural and electrophysiological integrity of the adult heart through Sprr1a repression

The FEBS Journal, EarlyView.
Chd4/NuRD and ThPOK cooperate to maintain transcriptional repression and nuclear organization in adult cardiomyocytes. Chd4 loss reduces miR‐150‐5p, relieving repression of Sprr1a, while ThPOK loss further enhances Sprr1a activation, possibly through altered chromatin–lamina interactions.
Fadoua El Abdellaoui‐Soussi, Apolonia Novillo, Rocío Brea, Marta Ysbert, Lorena Cussó, Gonzalo Pizarro‐Sánchez, Manuel Desco, Iván Hernández, Ángel Luis Armesilla, Ignacio Pérez de Castro, Alicia R. Folgueras, Juan Miguel Redondo, Pablo Gómez‐del Arco   +12 more
wiley   +1 more source